Bone marrow purging with mafosfamide--a critical survey.
Autologous bone marrow transplantation (ABMT) is increasingly used to consolidate remissions, primarily in hematological disease. Various purging strategies have been developed to minimize the risk of reimplantation of tumor cells with the bone marrow autotransplant. Pharmacological purging with the oxazaphosphorine derivative mafosfamide has been studied extensively, and recent clinical data suggest that purging with mafosfamide may translate into superior remission duration if compared to nonpurged ABMT in acute leukemia. Chemical and experimental data relevant to mafosfamide-purging and clinical results are reviewed, with special emphasis on safety aspects.
Sindermann
H
H
ASTA-Pharma AG, Department of Clinical Cancer Research, Frankfurt, Federal Republic of Germany.
Peukert
M
M
Hilgard
P
P
D000818:Animals; D001853:Bone Marrow / Q000187:drug effects*; D016026:Bone Marrow Transplantation; D055598:Chemical Phenomena; D002621:Chemistry; D003114:Colony-Forming Units Assay; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D006868:Hydrolysis; D007938:Leukemia / Q000628:therapy*; D051379:Mice
C048341:mafosfamide; D003520:Cyclophosphamide